In last trading session, Jasper Therapeutics Inc (NASDAQ:JSPR) saw 0.35 million shares changing hands with its beta currently measuring 2.73. Company’s recent per share price level of $3.33 trading at -$0.04 or -1.19% at ring of the bell on the day assigns it a market valuation of $50.02M. That closing price of JSPR’s stock is at a discount of -682.28% from its 52-week high price of $26.05 and is indicating a premium of 31.83% from its 52-week low price of $2.27. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.45 million shares which gives us an average trading volume of 617.05K if we extend that period to 3-months.
For Jasper Therapeutics Inc (JSPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Jasper Therapeutics Inc’s shares saw a change of -84.58% in year-to-date performance and have moved -5.13% in past 5-day. Jasper Therapeutics Inc (NASDAQ:JSPR) showed a performance of -38.45% in past 30-days. Number of shares sold short was 1.54 million shares which calculate 6.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 55.5 to the stock, which implies a rise of 94.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 65. It follows that stock’s current price would jump 9.91% in reaching the projected high whereas dropping to the targeted low would mean a gain of 9.91% for stock’s current value.
Jasper Therapeutics Inc (JSPR) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54.53% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 9.44% while estimates for its earnings growth in next 5 years are of 10.38%.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
Insiders are in possession of 1.27% of company’s total shares while institution are holding 87.94 percent of that, with stock having share float percentage of 89.07%. Investors also watch the number of corporate investors in a company very closely, which is 87.94% institutions for Jasper Therapeutics Inc that are currently holding shares of the company. VELAN CAPITAL INVESTMENT MANAGEMENT LP is the top institutional holder at JSPR for having 1.47 million shares of worth $32.55 million. And as of 2024-06-30, it was holding 9.8216 of the company’s outstanding shares.
The second largest institutional holder is SOLEUS CAPITAL MANAGEMENT, L.P., which was holding about 1.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.5157 of outstanding shares, having a total worth of $28.97 million.
On the other hand, T. Rowe Price Small-Cap Value Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025, the former fund manager was holding 438.89 shares of worth $1.46 million or 2.92% of the total outstanding shares. The later fund manager was in possession of 401.22 shares on Mar 31, 2025, making its stake of worth around $1.34 million in the company or a holder of 2.67% of company’s stock.